Neurimmune Holding AG
USPTO PatentsView assignee record - 18 granted patents across 8 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Neurimmune ranks #16,230 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 8 technology areas.
- #16,230
- of 49,997 US assignees by volume
- Top 42%
- by Innovation Score (38.1/100)
- 25.5
- avg claims per patent
- +13%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R16230 · Foreign Corporation #16,230 · 18 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-UP · BOOK-FULL
- GRANTS-MICRO 18 grants
- MID-PACK #16,230/49,997
- PHOTO-FINISH Nature Technology
- CPC-NARROW A61P · 8 areas
- INNOV-THIN 38.1/100
- CLAIMS-DENSE 25.5 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-UP +13% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Nature Technology Corporation (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Neurimmune’s 38.1 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Neurimmune
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Neurimmune Holding · this assignee
Neurimmune Holding · this assignee
38 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Neurimmune's Innovation Score is 38.1/100 (top 42% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Neurimmune?
Each dot is one of Neurimmune’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neurimmune’s own 25.5 claims/patent is ABOVE the 20.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Neurimmune's grants concentrate
Neurimmune Holding AG is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (4 grants) versus a trough of 1 in 2017. By volume, Neurimmune sits between Nature Technology Corporation and Ningbo VGR Electric Appliance Co., Ltd..
Neurimmune's three-year grant acceleration
Neurimmune Holding AG shows 4 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Neurimmune's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Nature Technology
Nature Technology Corporation
18 patents
- Nautilus Subsidia…
Nautilus Subsidiary, Inc.
18 patents
- Neodyne Bioscienc…
Neodyne Biosciences, Inc.
18 patents
- Netskrt Systems
Netskrt Systems, Inc.
18 patents
- Next Biometrics G…
Next Biometrics Group ASA
18 patents
- Next Level Ventur…
Next Level Ventures LLC
18 patents
- Nimble Robotics
Nimble Robotics, Inc.
18 patents
- Ningbo VGR Electr…
Ningbo VGR Electric Appliance Co., Ltd.
18 patents
- Neurimmune Holding ◀
Neurimmune Holding AG
18 patents
What this shows Neurimmune holds 18 patents at rank #16,239, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Neurimmune
By rank, the assignees closest to #16,239 in granted patent volume.
- Nature Technology Corporation #16,235 · 18 patents
- Nautilus Subsidiary, Inc. #16,236 · 18 patents
- Neodyne Biosciences, Inc. #16,237 · 18 patents
- Netskrt Systems, Inc. #16,238 · 18 patents
- Next Biometrics Group ASA #16,240 · 18 patents
- Next Level Ventures LLC #16,241 · 18 patents
- Nimble Robotics, Inc. #16,242 · 18 patents
- Ningbo VGR Electric Appliance Co., Ltd. #16,243 · 18 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Neurimmune's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Neurimmune's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
38 Top 42% higher than 58% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 11.1% |
| 2017 | 1 | 5.6% |
| 2018 | 1 | 5.6% |
| 2019 | 4 | 22.2% |
| 2020 | 2 | 11.1% |
| 2021 | 3 | 16.7% |
| 2022 | 2 | 11.1% |
| 2023 | 1 | 5.6% |
| 2024 | 1 | 5.6% |
| 2025partial year | 1 | 5.6% |
Which technologies does Neurimmune Holding AG patent most?
Top 8 of 8 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Neurimmune Holding AG's patent record in context - here's where to go next.
- Neurimmune Holding AG's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #16,230 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Neurimmune Holding AG against Nature Technology Corporation, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 38.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.